Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics (NASDAQ: EWTX), a biopharmaceutical company focused on muscle diseases, has granted equity-based inducement awards to 3 new non-executive employees. The awards include 84,250 stock options with an exercise price of $14.26 per share and 5,000 restricted stock units (RSUs).
The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will vest in four equal annual installments starting July 31, 2025. These awards were granted under the company's 2024 Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), una societ脿 biofarmaceutica specializzata nelle malattie muscolari, ha assegnato premi azionari a 3 nuovi dipendenti non esecutivi. Gli incentivi comprendono 84.250 opzioni su azioni con un prezzo di esercizio di 14,26 $ per azione e 5.000 unit脿 azionarie vincolate (RSU).
Le opzioni su azioni matureranno in 4 anni, con il 25% che matura dopo un anno e il resto che matura mensilmente. Le RSU matureranno in quattro rate annuali uguali a partire dal 31 luglio 2025. Questi premi sono stati concessi nell'ambito del Piano di Incentivi Azionari di Induzione 2024 della societ脿, in conformit脿 con la Regola di Quotazione Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), una empresa biofarmac茅utica centrada en enfermedades musculares, ha otorgado premios basados en acciones a 3 nuevos empleados no ejecutivos. Los premios incluyen 84,250 opciones sobre acciones con un precio de ejercicio de $14.26 por acci贸n y 5,000 unidades restringidas de acciones (RSUs).
Las opciones sobre acciones se consolidar谩n en 4 a帽os, con un 25% consolidado despu茅s de un a帽o y el resto consolid谩ndose mensualmente. Las RSUs se consolidar谩n en cuatro pagos anuales iguales a partir del 31 de julio de 2025. Estos premios se otorgaron bajo el Plan de Incentivos de Capital por Inducci贸n 2024 de la empresa, en cumplimiento con la Norma de Listado Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX)電� 攴检湣 歆堩櫂鞐� 欷戩爯鞚� 霊� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 3氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 欤检嫕 旮半皹 鞙犾澑 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 氤挫儊鞐愲姅 84,250欤检潣 鞀ろ啞 鞓奠厴鞚� 韽暔霅橂┌, 頄夓偓臧�瓴╈潃 欤茧嫻 14.26雼煬鞚搓碃 5,000欤检潣 鞝滍暅 欤检嫕 雼渼(RSU)霃� 韽暔霅╇媹雼�.
鞀ろ啞 鞓奠厴鞚� 4雲勳棎 瓯胳硱 甓岆Μ臧� 攵�鞐悩氅�, 1雲� 頉� 25%臧� 攵�鞐悩瓿� 雮橂ǜ歆�電� 毵れ洈 攵�鞐惄雼堧嫟. RSU電� 2025雲� 7鞗� 31鞚茧秬韯� 鞁滌瀾頃橃棳 4雲勳棎 瓯胳硱 鞐瓣皠 霃欖澕頃� 牍勳湪搿� 攵�鞐惄雼堧嫟. 鞚� 氤挫儊鞚� 須岇偓鞚� 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 Nasdaq 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅晿鞐� 攵�鞐悩鞐堨姷雼堧嫟.
Edgewise Therapeutics (NASDAQ : EWTX), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les maladies musculaires, a accord茅 des primes incitatives bas茅es sur des actions 脿 3 nouveaux employ茅s non cadres. Ces primes comprennent 84 250 options d'achat d'actions avec un prix d'exercice de 14,26 $ par action et 5 000 unit茅s d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une p茅riode de 4 ans, avec 25 % acquis apr猫s un an et le reste acquis mensuellement. Les RSU seront acquises en quatre versements annuels 茅gaux 脿 partir du 31 juillet 2025. Ces primes ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation en Actions 2024 de la soci茅t茅, conform茅ment 脿 la r猫gle de cotation Nasdaq 5635(c)(4).
Edgewise Therapeutics (NASDAQ: EWTX), ein biopharmazeutisches Unternehmen mit Fokus auf Muskelerkrankungen, hat aktienbasierte Anreizpr盲mien an 3 neue nicht-exekutive Mitarbeiter vergeben. Die Pr盲mien umfassen 84.250 Aktienoptionen mit einem Aus眉bungspreis von 14,26 $ pro Aktie sowie 5.000 Restricted Stock Units (RSUs).
Die Aktienoptionen werden 眉ber 4 Jahre unverfallbar, wobei 25 % nach einem Jahr und der Rest monatlich unverfallbar werden. Die RSUs werden in vier gleichen j盲hrlichen Tranchen ab dem 31. Juli 2025 unverfallbar. Diese Pr盲mien wurden im Rahmen des Inducement Equity Incentive Plans 2024 des Unternehmens gew盲hrt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
Each inducement stock option has an exercise price of
Each inducement RSU award shall vest as follows: one-fourth (1/4th) of the shares subject to each inducement RSU award shall vest on the first, second, third and fourth yearly anniversaries of July 31, 2025, subject to the employee's continued service.
Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to:聽聽or follow us on聽,听聽,听听补苍诲听.
View original content to download multimedia:
SOURCE Edgewise Therapeutics
FAQ
What inducement grants did Edgewise Therapeutics (EWTX) announce in August 2025?
What is the vesting schedule for EWTX's 2025 inducement stock options?
How will the RSUs granted by Edgewise Therapeutics in 2025 vest?
Under what authority did Edgewise Therapeutics grant these inducement awards?
